Piramal Pharma Q1 FY27 Results
Analysis based on 14 articles · First reported Jul 29, 2026 · Last updated Jul 29, 2026
The strong revenue growth and significant EBITDA margin expansion signal improved operational efficiency and market positioning, likely boosting investor confidence. The stock may see positive momentum as the results beat expectations, though the net loss remains a concern.
Piramal Group Limited announced its Q1 FY27 results for the quarter ended June 30, 2026. Revenue grew 17% year-on-year to INR 2,270 crore, driven by strong performance across all three businesses: CDMO (19% growth), Complex Hospital Generics (17% growth), and Consumer Healthcare (15% growth). EBITDA increased 72% to INR 285 crore, with margin expanding 400 basis points to 12.5%. The company reported a net loss of INR 69 crore, improved from a loss of INR 102 crore in Q1 FY26. Key highlights include the Sellersville facility receiving an EIR from the US FDA, inauguration of a commercial-scale payload-linker suite at Riverview (US), and collaboration with Ajinomoto Bio-Pharma Services for next-gen conjugation technology. The company also launched a new master brand 'i-choose' for women's intimate care. Chairperson Nandini Piramal expressed confidence in sustained growth.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard